Baricitinib - Eli Lilly/Incyte Corporation

Drug Profile

Baricitinib - Eli Lilly/Incyte Corporation

Alternative Names: INCB-028050; INCB-28050; LY-3009104; Olumiant

Latest Information Update: 25 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Incyte Corporation
  • Developer Eli Lilly; Incyte Corporation
  • Class Acetonitriles; Antipsoriatics; Antirheumatics; Azetidines; Pyrazoles; Pyrimidines; Pyrroles; Small molecules
  • Mechanism of Action Janus kinase 1 inhibitors; Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Rheumatoid arthritis
  • Phase II Atopic dermatitis; Giant cell arteritis; Systemic lupus erythematosus
  • Phase Unknown Psoriatic arthritis
  • Discontinued Diabetic nephropathies; Psoriasis

Most Recent Events

  • 14 Sep 2017 Adverse events and efficacy data from a phase II trial in atopic dermatitis released by Eli Lilly (NCT02576938)
  • 14 Sep 2017 Eli Lilly plans to imitate a phase III trial for atopic dermatitis in Q4 of 2017
  • 01 Sep 2017 Launched for Rheumatoid arthritis (Treatment-experienced) in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top